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Abstract

Objective: To compare treatment with stimulant medications to nonstimulant medications and/or
nonpharmacologic interventions on professional and interpersonal functioning in adults with
attention-deficit/hyperactivity disorder (ADHD).
Method: Systematic literature review of five databases; 22 articles containing 323 studies
(N=21,370) were included in this review.
Results: Psychostimulants remain the most studied treatment for adults with ADHD and boast
larger effect sizes than nonstimulant and nonpharmacologic therapy. Among nonpharmacologic
therapy, cognitive behavior therapy (CBT) has proven most successful in randomized controlled
trials. Effects of CBT are enhanced when combined with pharmacotherapy.
Conclusions: Psychostimulants continue to be the most frequently prescribed treatment for
adults with ADHD. Nonstimulant medications and nonpharmacotherapy remain used as an
adjunct or alternative to psychostimulant therapy, but show promise in producing long-term
improvements in professional and interpersonal functioning in adults with ADHD.
Keywords: ADHD, adult, stimulants, stimulant medication, nonstimulant medication,
nonpharmacologic, pharmacologic, methylphenidate, atomoxetine, cognitive behavior therapy
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Treatment of Adults with Attention-Deficit/Hyperactivity Disorder:
A Systematic Literature Review
Attention-deficit/hyperactivity disorder (ADHD) is a condition that initially presents in
childhood, affecting 5-7.2% of children (APA, 2013; Alyagon et al., 2020). While it was
originally thought that the disorder would be outgrown, it is now known that up to 65% of
children will continue to experience difficulty with attention and executive functioning into
adulthood (Aoshima-Kilroy et al., 2017; Baird et al., 2019; De Crescenzo et al., 2017; Geffen &
Forster, 2018; Goto et al., 2013; Lenzi et al., 2017; Schwarz, 2016; Smith et al., 2020). The
condition affects more than 2.5% of adults in the United States and over 4% of adults worldwide
(APA, 2013; Alyagon et al., 2020; Baird et al., 2019; Boland et al., 2020). Adults with ADHD
may experience increased difficulty with relationships, academics, and maintenance of
employment when compared to their peers (Boland et al., 2020; Corbisiero et al., 2018; Geffen et
al., 2018; Goto et al., 2017). Comorbid substance use, anxiety, and mood disorders are present in
up to 70% of adults with ADHD. Untreated adults with ADHD experience increased rates of
accidental injury and premature mortality (Aoshima-Kilroy et al., 2017; APA, 2013; Boland et
al., 2020; Corbisiero et al., 2018; De Crescenzo et al., 2017; Geffen et al., 2018; Lenzi et al.,
2017).
The DSM-V (2013) defines ADHD as a neurodevelopmental disorder characterized by a
“persistent pattern of inattention and/or hyperactivity-impulsivity that interferes with functioning
or development”. It is characterized by the presence of at least one of the following criteria:
Inattention or hyperactivity and impulsivity. Inattention is defined as having five or more of the
following symptoms: Careless mistakes, difficulty sustaining attention, mind wandering, failure
to complete tasks, difficulty with organization, avoidance of activities that require sustained
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mental effort, often losing necessary objects, is easily distracted, and/or is often forgetful (APA,
2013). To meet the criteria for hyperactivity and impulsivity, at least five of the following
symptoms must be present: Frequent fidgeting, inability to remain seated, restlessness, inability
to engage in quiet activities, is often “on the go” and unable to be still for prolonged periods of
time, talks excessively, engages in interrupting behaviors, and/or has difficulty waiting their turn
patiently (APA, 2013). The symptoms required to meet the criteria for inattention, hyperactivity,
or impulsivity make up the core symptoms of ADHD.
ADHD may be predominantly inattentive type, hyperactive/impulsive type, or may be a
combined presentation of the two. The symptoms must be present prior to age 12, in two or more
settings (home, school, work, extracurriculars, or leisure), and pervasively interfere with
functioning (APA, 2013). While the condition may co-occur with other mental disorders, the
symptoms should not occur exclusively with flare-ups of these disorders (APA, 2013). Adults
with ADHD may present differently than children and complain of inattention, restlessness, and
emotional dysregulation rather than disruptive behaviors; they also tend to be more talkative than
their peers (Baird et al., 2019).
Standardized Tools
The standardized tools used to measure outcomes are highlighted in Table 4 of the
appendix. The most common tools used were the Adult ADHD Self-Report Scale Symptoms
Checklist (ASRS), Conners’ scales (both self- and observer-rated), Barkley scales, the
Behavioural Rating Inventory for Executive Functioning (BRIEF-A), Wender scales, and
Clinical Global Impressions (CGI) scales. Occupational functioning was measured using
Endicott Work Productivity Scale (EWPS) and the Canadian Occupation Performance Measure
(COPM). Various measures, in addition to structured interviews, were used to assess quality of
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life, self-esteem, and self-efficacy. Standardized tools to measure comorbid conditions were used
to determine levels of anxiety, depression, and suicidality, though these conditions were not
studied in this review.
Pharmacologic Interventions
Psychostimulant Pharmacotherapy
Psychostimulant medications work by blocking reuptake of dopamine and
norepinephrine, thus increasing synaptic concentration of these neurotransmitters (AoshimaKilroy et al., 2017). Use of these medications are considered the first-line treatment for adults
with ADHD (Baird et al., 2019). Formulations may be immediate, intermediate, or long-acting
and should be tailored to meet the individual’s needs (De Crescenzo et al., 2017). Common side
effects of these medications include anxiety, gastrointestinal upset, appetite suppression,
headache, sleep disturbances, fatigue, and blunted affect (Aoshima-Kilroy et al., 2017; Baird et
al., 2019). Because these medications promote vasoconstriction, they can increase blood pressure
and may raise the risk of cardiovascular events including myocardial infarction (Aoshima-Kilroy
et al., 2017). Rarely, these medications may instigate seizure, psychosis, suicidality, priapism,
and hepatotoxicity (Aoshima-Kilroy et al., 2017). Caution should be exercised when prescribing
these medications for persons who experience hyperthyroidism, glaucoma, epilepsy, or severe
anxiety disorder. They should not be used within two weeks of taking an MAOI or with those
who experience cardiomyopathy, abnormal QT interval (prolonged or shortened), Brugada
syndrome, Wolff-Parkinson-White syndrome, anorexia, psychosis, or Marfan syndrome
(Aoshima-Kilroy et al., 2017). Because they are classified as a Schedule II drug with high
potential for misuse and diversion by the Food and Drug Administration, prescribers must take
part in the Prescription Monitoring Program (Aoshima-Kilroy et al., 2017).
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Psychostimulant medications have been used in pregnancy for women with moderate to
severe symptoms. However, placental perfusion may be impacted by the vasoconstrictive actions
of psychostimulant medications and their use is associated with an increased risk for preeclampsia (1.3 fold increase when taken in the first trimester) and pre-term birth (Cohen et al.,
2017). Benefits of the medication must be weighed against the risks of not treating women with
severe ADHD as untreated women may experience increased anxiety and aggression that may
interfere with self-care during pregnancy (Cohen et al., 2017).
Nonstimulant Pharmacotherapy
Atomoxetine. Atomoxetine, a noradrenaline reuptake inhibitor, works by promoting
neurotransmitters noradrenaline and dopamine in the prefrontal cortex thus improving attention
(Aoshima-Kilroy et al., 2017; Geffen et al., 2018). Insomnia, sedation, dizziness, gastrointestinal
dysfunction, sexual dysfunction, increased blood pressure, and anticholinergic effects (dizziness,
dry mouth, urinary retention, and increased heart rate) are common side effects (Aoshima-Kilroy
et al., 2017; AthenaHealth, 2020). Atomoxetine may cause liver damage and regular monitoring
of liver function tests is necessary (Aoshima-Kilroy et al., 2017; AthenaHealth, 2020).
Bupropion. Bupropion is an aminoketone antidepressant. Its therapeutic effect is derived
from its action of inhibiting reuptake of dopamine and noradrenaline (AthenaHealth, 2020;
Verbeeck et al., 2017). Bupropion is structurally similar to psychostimulants, which translates to
a similar, but less robust, action without the high risk of misuse and diversion that
psychostimulants boast (Verbeeck et al., 2017). Headache, nausea, dry mouth, and insomnia are
common side effects; additionally, bupropion lowers the seizure threshold, thus increasing
seizure risk (AthenaHealth, 2020; Verbeeck et al., 2017). This medication may be effective for
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the nearly 19% of adults with ADHD who experience comorbid major depression (CHADD,
2019).
Desipramine. Desipramine, a tricyclic antidepressant, inhibits norepinephrine and
serotonin reuptake (AthenaHealth, 2020). It may be useful for adults who experience both major
depressive disorder and ADHD. Desipramine has the potential for many adverse effects, the
most common being drowsiness, anticholinergic effects (dry mouth, constipation, urinary
retention), dizziness, palpitations, tachycardia, and gastrointestinal distress; it may also increase
anxiety and agitation and cause restlessness and insomnia (AthenaHealth, 2020). Serious adverse
effects include changes in blood pressure (hyper- or hypotension), cardiac arrhythmias, QT
prolongation, torsades de pointes, and AV block. It may cause myocardial infarction,
cerebrovascular accident, extrapyramidal symptoms and tardive dyskinesia, serotonin syndrome,
psychosis, suicidality, hepatitis, and angioedema (AthenaHealth, 2020). Unlike psychostimulant
medications, desipramine cannot be stopped abruptly. While taking the medication, providers
should monitor therapeutic drug levels, suicidality, and behavior changes. Desipramine should be
used with caution for anyone with a history of cardiovascular disease, electrolyte abnormalities,
QT prolongation, torsades de point, arrhythmias, angle-closure glaucoma, seizure disorder,
thyroid disease, diabetes mellitus, psychosis, Parkinson’s disease, or alcohol abuse
(AthenaHealth, 2020).
Nonpharmacologic Interventions
Nonpharmacologic therapy may be used as an alternative to pharmacotherapy by persons
who are unable to tolerate, whose symptoms are inadequately controlled by, or who do not wish
to take medication. While there are many nonpharmacologic options for symptom control in
adults with ADHD including hypnotherapy, neurofeedback, self-monitoring, and psychotherapy
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in the form of cognitive behavior therapy (CBT); CBT has been the most studied. CBT was
developed in the 1960’s; however, only recently has this therapy been integrated into ADHD
treatment (CHADD, 2021). CBT addresses ADHD symptoms by teaching organizational,
executive functioning, and emotional regulation skills (CHADD, 2021). Mindfulness meditation
has been used to improve emotional regulation (Bachman et al., 2016; De Crescenzo et al.,
2017). Non-invasive brain stimulation has been FDA approved to treat depression and
obsessive/compulsive disorder and has been postulated to improve ADHD symptoms (Alyagon
et al., 2020).
While psychostimulants have been recommended by guidelines as the first-line therapy
for ADHD in adults, these medications carry the risk of adverse effects. Up to 50% of adults
taking psychostimulant medication discontinue their use within three years (Smith et al., 2020;
Verbeeck et al., 2017). For those who do continue psychostimulant therapy, many are left with
incomplete symptom coverage, unwanted side-effects, and difficulty functioning during times
when medication is not taken (Cherkasova et al., 2016). The purpose of this literature review is
to compare treatment using psychostimulant medications to nonstimulant medications and/or
nonpharmacologic interventions on professional and interpersonal functioning in adults with
attention-deficit/hyperactivity disorder (ADHD).
Method
Databases
A literature search was performed using five electronic databases, including Academic
Search Premier, CINAHL, PubMed, ProQuest: Nursing and Allied Health Database, and
PsychArticles. These databases were chosen based on their content of health-related and
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neuropsychiatric-related articles. Descriptions of each database can be found in Table 1 of the
Appendix.
Study Selection and Search Strategies
The protocol for critically appraising evidence outlined by Melnyk and Overholt (2019)
guided this systematic review of the literature. The search terms are outlined in Table 2 of the
Appendix. The search was limited to scholarly, peer-reviewed articles in the English language.
Studies published between January 2015 and January 2021 were eligible for consideration in
order to provide the most recent research available. Articles considered for inclusion must have
1) included pharmacologic and/or nonpharmacologic therapy for adults with ADHD and 2)
evaluated observed and/or perceived effects to symptoms and professional and/or interpersonal
functioning using standardized tools. Exclusion criteria included studies that involved children or
adolescents, and those that investigated ADHD with comorbid psychiatric conditions, substance
abuse, or pregnancy. Articles that were not available in full text were also excluded.
As shown in the Figure 1, a search of the included databases resulted in 563 articles,
which were screened at the abstract level and reduced to 43 articles. Those remaining articles
were read in their entirety and 21 were excluded according to the criteria noted above with
detailed reasons outlined in Table 3 of the Appendix. Twenty-two articles met final inclusion
criteria for this review. Reference Table 4 for details regarding each study that was included.
The studies contained data from around the world. Of the 22 articles, five were conducted
in North American, seven were from Europe, two were from the Middle East, and one study was
completed in Asia. The remaining articles either did not specify the country the study took place
in or drew from multiple countries.
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Close observation was given to study design, intervention, and primary and secondary
outcomes. Of the 22 studies included, 21 were quantitative. One qualitative study was included
to provide insight on what drives adults with ADHD to choose and maintain treatment. Due to
the small size of this qualitative study, caution should be used generalizing the data to larger
populations. Risk of inherent bias was present in many of the studies due to concealment of
randomization process. An additional limitation to this review was the volume of included
studies. Multiple meta-analyses were included in this review and some of the studies were
duplicated within these analyses. Enacting more strict search parameters or limiting metaanalyses would have yielded a more manageable dataset.
Figure 1
Prisma Flow Diagram

Literature Review
Study Characteristics
Publication Dates
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2015-2016

3

2017-2018

11

2019-2021

7

Geographical Location
North America

5

Europe

7

Middle East

2

Asia

1

Multiple Countries or 7
Otherwise Unspecified
Treatment
Total Studies: 342
Sample Size

N=21,370

Stimulant Therapy

N=9,944

Nonstimulant Therapy

N=5,500

Non-pharmacotherapy

N=164

Multi-Modal

N=92

Effects of Interventions
Stimulant Medication
Psychostimulant therapy is the most studied therapy for adults with ADHD. Their use is
associated with improved core symptom control and increased attention (Fuermaier et al., 2016).
Methylphenidate has been shown to be more efficacious in improving cognitive function, work
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productivity, and emotional dysregulation leading to improved quality of life when compared to
other psychostimulants, nonstimulant medications, and placebo (Goodman et al., 2017; Lenzi et
al., 2018). These improvements were shown through both provider- and self-rated standardized
tools. While Baird et al. (2019) found that amphetamine use was not effective in improving
global functioning or reducing co-existing anxiety and/or depression symptoms, a meta-analysis
by Boland et al. (2020) discovered the opposite – psychostimulant use showed protective effects
on mood disorders (p<0.001) and risk-behaviors with significant improvements to overall
functioning compared to no medication (p<0.001). A meta-analysis by Elliot et al. (2020)
revealed that use an any ADHD pharmacotherapy (psychostimulant or nonstimulant
medications) was associated with a statistically significant improvement in executive functioning
(95% CI [-7.15, -4.29]) with low risk of harms (95% CI [0.67, 2.18]). While psychostimulants
boast larger effects than nonstimulant medications or nonpharmacologic therapy (p<0.00001),
their use is also associated with more frequent adverse events (p=0.006) (Cunill et al., 2016).
Nonstimulant Medication
While nonstimulant medications are more efficacious than placebo at reducing core
ADHD symptoms, they are not as effective as psychostimulant medications in randomized
controlled trials (De Crescenzo et al., 2017). Atomoxetine is the most studied among the
nonstimulant medications. It has been shown to reduce core ADHD symptoms and improve
executive functioning with fewer adverse effects than psychostimulant medications (p<0.001)
(Goto et al., 2017). Those receiving atomoxetine also experienced improvements in quality of
life (p<0.001), life outlook (p<0.05), productivity (p<0.001), and relationships (p=0.007) (Goto
et al., 2017). According to a study by Verbeeck et al. (2017), bupropion proved superior to
placebo in reducing core ADHD symptom severity (95% CI [-0.86, -0.15]) with similar
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tolerability to placebo (95% CI [0.35, 4.10]), though the evidence was of low quality. Bupropion
and desipramine may be a useful treatment when considering pharmacotherapy for adults who
have co-existing mood disorder as their primary use is for the treatment of depression.
Nonpharmacologic Therapy
Multiple nonpharmacologic therapies were studied in this literature review. Various
forms of psychotherapy have been shown to be beneficial in reducing core ADHD symptoms for
individuals with mild ADHD or those with incomplete symptom management despite
pharmacotherapy (Groß et al., 2019). CBT has the most support as a viable treatment for adults
with ADHD, however results are not as rapid as pharmacotherapy and effect sizes remain much
smaller than treatment with psychostimulants alone (Smith et al., 2020). And while it has been
shown to be effective, there are few studies that compare CBT without the addition of
pharmacotherapy (Groß et al., 2019). When used in addition to pharmacotherapy, CBT has been
shown to significantly reduce core ADHD symptoms and improve both occupational and social
functioning when compared to standard treatment with pharmacotherapy alone (Dittner et al.,
2018; Groß et al., 2019). The medium-to-large effects of CBT are apparent regardless of whether
or not pharmacotherapy is used (Knouse et al., 2017). Improved perceived anxiety, depression,
and distress are secondary benefits of CBT in adults with ADHD (Dittner et al., 2018).
Additional secondary benefits include improved time-management, organization, and planning
skills, as well as increased knowledge and motivation for self-care (Smith et al., 2020). A further
finding is continued statistically significant effects up to 18 months after treatment had ended
when compared to usual care (Groß et al., 2019). Conversely, Corbisiero et al. (2018) found that
the addition of CBT to stimulant pharmacotherapy was no more effective than standard clinical
management consisting of 30 minutes of medication counseling and supportive therapy by
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trained clinicians; this finding was, however, an outlier compared to the majority of the research
described above.
Mindfulness meditation and mindfulness-based CBT were shown to significantly
improve self-regulation, attention, and emotional control (Bachman et al., 2016; De Crescenzo et
al., 2017; Janssen et al., 2018). When combined with pharmacotherapy, mindfulness-based CBT
significantly reduced perceived and clinician-rated core ADHD symptoms with effects lasting
through six months of follow-up (Janssen et al., 2019). While immediate effects on executive
functioning were not observed with mindfulness-based CBT, this domain was improved at the
six-month follow-up (Janssen et al., 2019).
Interventions targeting executive functioning skills such as establishing a routine,
organization, and time management was shown to improve outcomes in women with ADHD
(Gutman et al., 2020). Additional interventions that have been shown to improve executive
functioning include stress management and environmental control by reducing distractions
(Gutman et al., 2020). Prefrontal brain stimulation, similar to what has been used for mood
disorders, has shown some promise in one small study. However, the treatment may cause
physical discomfort and the long-term effects remain unknown (Alyagon et al., 2020). Other
nonpharmacologic approaches, such as hypnotherapy and neurofeedback were not shown to be
effective when compared to sham therapy (Smith et al., 2020).
Gaps in Literature
Multi-modal therapy is recommended for adults with ADHD. However, there is a paucity
of studies that evaluate the long-term outcomes of multimodal therapy on symptom control and
overall functioning. Additionally, little information exists on barriers to psychotherapy uptake
among adults with ADHD.
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Discussion

Current guidelines recommend long-acting psychostimulant medication
(methylphenidate) as first-line treatment for adults with ADHD who have significant impairment
in at least one domain (ADHD Institute, 2019; National Institute for Health and Care Excellence
(NICE), 2019). Use of such medications may result in more than 30% improvements in core
symptom reduction (Grade B recommendation) (Baird et al., 2019). Nonstimulant medications
remain second-line treatment for adults with ADHD, and may be used in place of or as an
adjuvant to psychostimulant medications. Multimodal therapy, including psychotherapy, is also
recommended, though not widely utilized (ADHD Institute, 2019; Geffen et al., 2018; Groß et
al., 2019; Lenzi et al., 2017; NICE, 2019). The risks and benefits of ADHD treatment in adults
should be carefully considered and the decision on how to treat the symptoms should occur
through shared decision making (Boland et al., 2020; Druedahl & Sporrong, 2018; Elliot et al.,
2020; Groß et al., 2019; Verbeeck et al., 2017).
Pharmacotherapy has proven both safe and efficacious through numerous randomized
controlled trials. Both memory and executive function, as well as emotional dysregulation, may
be improved, though not normalized, using psychostimulant medications (Fuermaier et al., 2016;
Lenzi et al., 2018). Unfortunately, benefits cease when the medication is discontinued or a dose
is missed, and effects may be reduced over time. The addition of psychotherapy, specifically
CBT, may be a means of bridging this gap and providing skills to improve long-term executive
functioning which leads to improved social, occupational, and global functioning (Fuermaier et
al., 2016; Janssen et al., 2019). While studies highlight that psychotherapy is less efficacious
than pharmacotherapy, these options for treatment should be shared for all those who cannot
tolerate or do not wish to undergo pharmacotherapy, or offered in addition to pharmacotherapy
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for enhanced core symptom control (Cherkasova et al., 2016; Dittner et al., 2018; Groß et al.,
2019; Knouse et al., 2017). Discontinuation rates of psychostimulant therapy may be upwards of
50% for reasons ranging from feelings of not being oneself and unsatisfactory symptom control
to bothersome adverse effects (Druedahl et al., 2018; Verbeeck et al., 2017). Discontinuation
rates may be mitigated with the addition of psychotherapy as pharmacotherapy provides
immediate relief while individuals learn skills to cope with their ADHD (Alyagon, 2020; Cunill
et al., 2016). It is worth noting that one study by Corbisiero et al. (2018) did not show CBT to be
any more efficacious than standard clinical management when used in addition to
pharmacotherapy. This study’s findings, however, were contrary to the remaining studies in this
review. It should be noted that there were obvious limitations of this study including small
sample (N=43) and uneven distribution of comorbid conditions between the control and
intervention groups.
In fact, Druedahl et al. (2018) found that many adults desired nonpharmacologic
treatment for their ADHD but felt that they lacked knowledge about their options. Despite
scientific studies boasting the effectiveness of therapies such as CBT, mindfulness, or skills
training and recommendations for multimodal therapy, nonpharmacologic options remain a
largely underutilized treatment for adults with ADHD in the United States. The key is to offer
transparency in the course of treatment; while medications often provide immediate results, the
effects of nonpharmacologic therapeutic options are more gradual, yet also longer lasting (De
Crescenzo et al., 2017). Additionally, psychotherapy may be substantially costlier than
pharmacotherapy (Druedahl et al., 2018).
Limitations
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While this review of literature was useful in uncovering the continued needs for research
on nonpharmacologic and multimodal therapy in adults with ADHD, it did not address how to
approach treatment of ADHD in adults with co-morbid substance use disorder. Substance use
disorder has been shown to increase the risk of stimulant misuse (De Crescenzo et al., 2017).
Implications for Future Practice
Recommendations for Clinical Practice
Primary care nurse practitioners and other medical providers should address biases
related to diagnosis of adult ADHD and treatment with psychostimulant medications.
Additionally, providers should increase their knowledge of nonpharmacologic therapies to use in
addition to pharmacotherapy to optimize symptom management and professional and
interpersonal functioning.
Recommendations for Research
Further research is needed on the long-term outcomes of treatment with psychostimulants
compared with psychotherapy. Is CBT not well-utilized due to lack of knowledge on its efficacy
or due to lack of providers who practice this form of therapy? Further research is warranted to
explore barriers to CBT in adults with ADHD.
Recommendations for Health Policy
Currently, there is a scarcity of professionals trained to implement CBT for those
diagnosed with ADHD. Increasing provider training in CBT, coping skills, and executive
functioning training may translate to increased uptake of multi-modal therapy in adults with
ADHD.
Conclusions
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Psychostimulants remain the first-line treatment option for adults with ADHD, with
nonstimulant medications and nonpharmacologic options considered second-line treatments that
should be used in addition to psychostimulants or for those who are unable to tolerate
psychostimulants. Nonpharmacologic options may also be considered as first-line treatment for
individuals who express concern over a desire to not become reliant on medications. Regardless
of the therapeutic option chosen, the patient’s individual concerns and life situation should be
considered and the choice should be made through shared decision making after risks and
benefits of all options have been discussed.
In the absence of referral for psychotherapy, primary care nurse practitioners caring for
adults with ADHD may provide counseling on nonpharmacologic interventions to manage their
symptoms to enhance pharmacotherapy. Education on environmental management, such as
establishing routines, working in a quiet, clutter-free setting, and minimizing distractions,
coupled with stress-management techniques may be used to complement pharmacotherapy.
Ensuring that primary care providers managing adults with ADHD are following the most
current evidence and prescribing multimodal therapy is paramount in arming adults with ADHD
with the tools they require to successfully manage their disorder.
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Excluded

Savulich, G., Thorp, E., Piercy, T., Peterson, K. A., Pickard, J. D., & Sahakian,
B. J. (2019). Improvements in attention following cognitive training with the
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Excluded

Excluded

Excluded

Rationale
include lack of differentiation between individuals with and without
comorbid conditions and inability to analyze outcomes based on
ADHD subtype
Did not meet inclusion criteria due to comorbid cocaine use

Sample size was small with low power. The trial did not factor in
medication use, which some participants used and some did not.
Though the study did show an improvement in those using an
internet-based CBT program, I did not feel that the study was robust.
Article does not meet inclusion requirements as the article addresses
cognitive distortions and mindsets as a foundation for understanding
treatment of adults with ADHD. While the information is useful to
practice, it does not generate new information on the treatment of
adults with ADHD
The article used a sample of adults with no psychiatric diagnosis (past
or current), including ADHD

Included

Systematic review of nonpharmacologic interventions for adults with
ADHD

Excluded

Randomized, placebo controlled within-subjects cross-over trial
Explores the effects of atomoxetine in the adult reward center of the
brain, but not the adult with ADHD

Excluded

RCT on the effect of methylphenidate on brain structure which does
not meet inclusion requirements. Consideration of use in introduction
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Systematic review assessing the efficacy of bupropion as therapy for
adults with ADHD
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http://doi.org/10.1037/pha0000093
Yang, Z., Kelly, C., Castellanos, F. X., Leon, T., Milham, M. P., & Adler, L.
A. (2016). Neural correlates of symptom improvement following stimulant
treatment in adults with attention-Deficit/Hyperactivity disorder. Journal of
Child and Adolescent Psychopharmacology, 26(6), 527-536.
http://dx.doi.org.ezproxy.mnsu.edu/10.1089/cap.2015.0243
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Included or
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Rationale

Excluded

Article addresses prescription stimulant medication misuse that is not
specific to adults with ADHD

Excluded

The study examined the effects of amphetamines on the prefrontal
cortex of the brain. Consideration of inclusion into the introduction

Excluded

The study focused on emotional lability associated with ADHD and
not functional status
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Table 4
Literature Review Table of All Studies Included
Citation

Study Purpose

Pop (N)/
Sample
Size (n)
/Setting(s)

Design/
Level of
Evidence

Variables/
Instruments

Intervention

Findings

Implications

Alyagon U., Shahar H., Hadar A.,
Barnea-Ygael N., Lazarovits A.,
Shalev H., & Zangen A. (2020).
Alleviation of ADHD symptoms
by non-invasive right prefrontal
stimulation is correlated with
EEG activity. Neuroimage:
Clinical, 26(102206).
Https://doi.org/10.1016/j.nicl.202
0.102206

To evaluate
whether
targeting the
right prefrontal
cortex (rPFC)
with multiple
sessions of
repetitive
transcranial
magnetic
stimulation
(rTMS) will
affect clinical
symptoms in
adults suffering
from ADHD
To highlight the
mechanisms of
mindfulness
meditation.

N=43 drugfree adults
with
ADHD;
Israel

I

Conners’ Adult ADHD
Rating Scale (CAARS);
Barkely Adult ADHD
Rating Scale (BAARSIV);
Behavioral Rating
Inventory for Executive
Functioning (BRIEFA);
Beck Depression
Inventory (BDI)

rTMS; active
control;
sham
treatment

rTMS resulted in significant
improvement of symptoms
(p=0.00085)

rTMS is a safe and effective treatment
for ADHD

5
neuroimagi
ng studies;
3 clinical
studies;
Germany

I

Mindfulnessbased
cognitive
therapy

Mindfulness meditation may
reduce distractibility while
cognitive therapy aids in
improving coping and executive
functioning skills.

Mindfulness meditation as a
neurobehavioral intervention may help
adults with ADHD to improve selfregulation.

To evaluate the
safety and
efficacy of
amphetamines
in adults with
ADHD

19
randomized
controlled
trials with
N=2,521
adults with
ADHD;
US

I

Amphetamines provide a clinician
rated 30% reduction in ADHD
symptoms when compared with
placebo (Strength of
recommendation: B)

While amphetamines may reduce
clinician-rated symptoms in adults
with ADHD, they were not found to
improve global functioning or reduce
accompanying symptoms of anxiety
and depression. Use of amphetamines
are not without risk of adverse effects,
including increased anxiety, depressed
mood, nausea, vomiting, headache,
fatigue, insomnia, hypertension, and
flushing.

Bachmann, K., Lam, A. P., &
Philipsen, A. (2016).
Mindfulness-based cognitive
therapy and the adult ADHD
brain: A neuropsychotherapeutic
perspective. Frontiers in
Psychiatry, 27(7), 117.
https://doi.org/10.3389/fpsyt.2016
.00117
Baird, D., & Hoffman, A. (2019).
Use of amphetamines for
attention-deficit/hyperactivity
disorder in adults. American
Family Physician, 100(5), 278279. Retrieved on November 20,
2020 from
https://www.aafp.org/afp/2019/09
01/p278.html
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Citation

Study Purpose

Pop (N)/
Sample
Size (n)
/Setting(s)

Design/
Level of
Evidence

Boland, H., DiSalvo, M., Fried,
R., Woodworth, K. Y., Wilens,
T., Faraone, S. V., & Biederman,
J. (2020). A literature review and
meta-analysis on the effects of
ADHD medications on functional
outcomes. Journal of Psychiatric
Research, 123, 21–30.
https://doi.org/10.1016/j.jpsychire
s.2020.01.006

To conduct a
systematic
review and
meta-analysis
of literature
from large
databases and
registries to
assess the
effects of
ADHD
medication on
associated
functional
outcomes.
Evaluate the
effects of group
CBT alone
versus
combined with
medication on
ADHD
symptoms and
functional
outcomes in
adult patients.

40 articles
included in
literature
review; 21
studies
included in
metaanalysis;
No country
stated

I

88 adults
with
ADHD;
N=46
without
medication;
N=42 with
medication;
Canada

I

To analyze the
contribution of
psychotherapy
to the treatment
of adult ADHD
patients.

N=43
ADHD
patients;
N=20 CBT
+ med;
N=23 SCM
+ med;
Switzerland

I

Cherkasova, F., French, L. R.,
Syer, C. A., Cousins, L., Galina,
H., Kashani, Y. A-, & Hechtman,
L. (2016). Efficacy of cognitive
behavioral therapy with and
without medication for adults
with ADHD: A randomized
clinical trial. Journal of Attention
Disorders, 24(6), 889–903.
https://doi.org/10.1177/10870547
16671197

Corbisiero, S., Bitto, H., Newark,
P., Mörstedt, B. A-, Elsässer, M.,
Kammermann, J. B-, Künne, S.,
Nyberg, E., Fallahpour, M. H-, &
Stieglitz, R. D. (2018). A
comparison of cognitivebehavioral therapy and

Variables/
Instruments

Cognitive behavior
therapy with and
without medication;
Conners’ Adult ADHD
Diagnostic Interview for
DSM-IV (CAARD-D);
Barkley Current ADHD
Symptoms Scale;
Conners’ Adult ADHD
Rating Scale (CAARS);
Barkley Childhood
ADHD Symptoms
Scale;
Wender Utah Rating
Scale;
Wechsler Adult
Intelligence Scale-III;
Wechsler Memory
Scale-III;
Wide Range
Achievement Test-3
Methylphenidate; CBT
Structured clinical
interview for DSM-IV
(SCID-I and SCID-II);
Conners’ Adult ADHD
Diagnostic Interview for
DSM-IV (CAADID);
Conners’ Adult ADHD
Rating Scale (CAARS);

Intervention

Findings

Implications

Pharmacotherapy is associated
with a decreased risk of negative
ADHD-associated functional
outcomes.

Early diagnosis and treatment of
individuals with ADHD may improve
functional outcomes.

CBT – 12
sessions at
1.5 hours
each
administered
by a PhDlevel
therapist;
Medication –
methylpheni
date or
amphetamine
, gradually
increased
over the
course of the
study

CBT, both with and without
medication, resulted in significant
improvements relative to baseline
in ADHD symptoms and
functional outcomes; CBT with
medications was superior to CBT
alone in reducing both self- and
observed ADHD symptoms
immediately while CBT alone
improve more gradually. The
CBT only group continued to
improve after discontinuation of
the CBT intervention, while this
was not observed with the CBT
plus medication group.

CBT without medication is a viable
option for those who cannot, or do not
wish to, take stimulant medications.

Methylpheni
date 20
mg/day,
titrated up
every 4 days
to a level of
0.5-1.3
mg/kg daily.
If

Individualized CBT program was
not able to outperform standard
clinical management (SCM).

More information is needed to
determine the effects of CBT therapy
in addition to pharmacotherapy in
adults with ADHD
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Study Purpose

Pop (N)/
Sample
Size (n)
/Setting(s)

Design/
Level of
Evidence

pharmacotherapy vs.
pharmacotherapy alone in adults
with attentiondeficit/hyperactivity disorder
(ADHD) -- A randomized
controlled trial. Frontiers in
Psychiatry, 9(571).
http://doi.org/10.3389/fpsyt.2018.
00571

Cunill, R., Castells, X., Tobias,
A., & Capellà, D. (2016).
Efficacy, safety and variability in
pharmacotherapy for adults with
attention deficit hyperactivity
disorder: A meta-analysis and
meta-regression in over 9000
patients. Psychopharmacology, 2
33(2), 187-197.
http://dx.doi.org.ezproxy.mnsu.ed
u/10.1007/s00213-015-4099-3

To further
understand the
factors
underlying the
variability in
the results of
RTCs assessing
pharmacologica
l interventions
for adults with
ADHD.

44 studies
involving
N=9952
patients;
Atomoxetin
e=12
studies/N=
3703);
Bupropion
=5
studies/N=
329;
Dexamphet
amine=1

I

Variables/
Instruments

Intervention

Conners’ ADHD Adult
Rating Scale SelfReport Short Version
(CAARS-S:S);
Conners’ Adult ADHD
Rating Scale Observer
Long Version (CAARSO:L);
Wender-Reimherr Adult
Attention Deficit
Disorder Rating Scale
(WRAADDS);
ADHD Self-Rating
Behavior Questionnaire
(ADHD-SR);
Sheehan’s Disability
Scale (SDS);
Adult AttentionDeficit/Hyperactivity
Disorder Quality-ofLife Scale (AAQol);
General Perceived SelfEfficacy Scale (SWE);
Rosenberg Self-Esteem
Scale (RSES);
Psychotherapy
Motivation
Questionnaire (FMP);
Bern Post Session
Report
Systematic review of
RCTs

methylpheni
date was not
tolerated, an
equivalent
dose of
Concerta
was given;
CBT 10-12
sessions
individualize
d to ADHD

Stimulant
therapy;
nonstimulant
therapy;
psychotherap
y

Findings

Implications

Pharmacological treatment was
efficacious in reducing ADHD
symptoms (p<0.00001) with
stronger effect size with stimulant
medications (Diff SMD=0.18,
p=0.017); treatment with
pharmacologic agents was
associated with more frequent
adverse effects (p=0.006).

Efficacy of stimulant medication is
greater than non-stimulant
medications. Must weight possible
symptom relief with risks of adverse
effects from treatment with stimulant
medications. Providers must monitor
for decreased efficacy of
pharmacotherapy over time.
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Citation

De Crescenzo, F., Cortese, S.,
Adamo, N., & Janiri, L. (2017).
Pharmacological and nonpharmacological treatment of

36
Study Purpose

To provide a
reliable
summary of the
best available
information to

Pop (N)/
Sample
Size (n)
/Setting(s)
study/N=49
;
Dexmethyl
phenidate=
1
study/N=22
1;
Desipramin
e=1
study/N=43
;
Lisdexamfe
tamine=3
studies/N=
613;
Mixed
amphetami
ne salts=3
studies/N=
655;
Methylphen
idate
OROS=10
studies/N=
2,340;
Other
methylphen
idate
formulation
=10
studies/N=
1,657;
Modafinil=
1
study/N=33
8
Multiple
countries/
Multiple
sites
40 studies;
N=778,298;
No country
specified

Design/
Level of
Evidence

Variables/
Instruments

Intervention

Findings

Implications

I

Systematic reviews;
recent guidelines on
adult ADHD

Pharmacothe
rapy;
nonpharmac
ologic
therapy;

Stimulant medications
(amphetamines) have higher
efficacy than other forms of
therapy,

Risks-versus-benefits of stimulant
medications should be considered
when treating adults with ADHD.
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Citation

Study Purpose

adults with ADHD: A metareview. Evidence - Based Mental
Health, 20(1), 4.
http://dx.doi.org.ezproxy.mnsu.ed
u/10.1136/eb-2016-102415
Dittner, H., Hodsoll, J., Rimes, K.
A., Russell, A. J., & Chalder, T.
(2018). Cognitive-behavioural
therapy for adult attention-deficit
hyperactivity disorder: A proof of
concept randomised controlled
trial. Acta Psychiatrica
Scandinavica, 137(2), 125–137.
https://doi.org/10.1111/acps.1283
6

inform practice
in adults with
ADHD.

Investigate
efficacy, patient
acceptability,
and feasibility
of formulationbased CBT for
adults with
ADHD

Druedahl, L. C., & Sporrong S.
K. (2018). Managing complexity:
Exploring decision making on
medication by young adults with
ADHD. Pharmacy (Basel), 6(2),
33.
https://doi.org/10.3390/pharmacy
6020033

Elliott, J., Johnston, A., Husereau,
D., Kelly, S. E., Eagles, C.,
Charach, A., Hsieh, S., Bai, Z.,
Hossain, A., Skidmore, B.,

Assess the
relative effects
of individual
pharmacologic
treatments for

Pop (N)/
Sample
Size (n)
/Setting(s)

Design/
Level of
Evidence

Variables/
Instruments

Intervention

Findings

Implications

Significant improvement of
symptoms as well as improved
self-rated anxiety and depression,
global distress, and patient
satisfaction

When added to treatment as usual,
CBT had greater success in reducing
ADHD symptoms and improving
occupational and social functioning
than treatment as usual (medication
management) alone.

Three major themes were revealed
through analysis of date:
1) Patient’s right to
choose ADHD
medication as
treatment
2) Patient’s decision of
whether or not to treat
ADHD with medication
3) Factors affecting
patient’s decision on whether
to take ADHD medication or
not
High or unclear risk of bias in
many studies; few differences
between medications.
Atomoxetine was associated with
improved patient-reported clinical

Understanding the factors influencing
treatment choices helps prescribers
empower patients

multimodal
therapy

60
participants
;
19
participants
in the CBT
group were
on
medication,
26
participants
in the TAU
group were
on
medication.
Medication
=stimulant
or
atomoxetin
e;
UK
10 adults
age 22-29
years of
age;
Denmark

I

Barkley Current
Symptoms Scale;
Work and Social
Adjustment Scale

VI

Focus group
Individual Interviews

81 trials;
N=12,423;
Country not
specified

I

16 sessions
CBT

Stimulant
pharmacotherapy;
Nonstimulant

The choice between ADHD
pharmacotherapies may depend on
individual patient considerations;
future studies should assess long-term
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Citation

Study Purpose

Tsakonas, E., Chojecki, D.,
Mamdani, M., & Wells, G. A.
(2020). Pharmacologic treatment
of attention deficit hyperactivity
disorder in adults: A systematic
review and network metaanalysis. PloS One, 15(10),
e0240584–e0240584.
https://doi.org/10.1371/journal.po
ne.0240584
Fuermaier, A. B. M., Tucha, L.,
Koerts, J., Weisbrod, M., Lange,
K. W., Aschenbrenner, S., &
Tucha, O. (2017). Effects of
methylphenidate on memory
functions of adults with ADHD.
Applied Neuropsychology: Adult,
24(3), 199-121.
https://doi.org/10.1080/23279095.
2015.1124108
Geffen, J., & Forster, K. (2018).
Treatment of adult ADHD: A
clinical perspective. Therapeutic
Advances in
Psychopharmacology, 8(1), 2532.
https://doi.org/10.1177/20451253
17734977.

adults with
ADHD

Goodman, D. W., Starr, H. L.,
Ma, Y. W., Rostain, A. L.,
Ascher, S., & Armstrong, R. B.
(2017). Randomized, 6-week,

To evaluate the
efficacy and
safety of
individualized
dosing within

Explore the
impact of
methylphenidat
e (MPH) on
memory
functions of
adults with
ADHD

Pop (N)/
Sample
Size (n)
/Setting(s)

N=108;
MPH group
N=36;
Non-MPH
group
N=36;
healthy
adults
without
ADHD
N=36;
Germany

To recognize
the importance
of adult ADHD,
overcome
anxiety about
the diagnosis,
and prevent
marginalization
of vulnerable
patients.
Informational
guideline.

Design/
Level of
Evidence

Variables/
Instruments

II

Intervention

Findings

Implications

pharmacotherapy

response and quality of life
compared with placebo. No
significant difference in risk of
serious adverse events or
treatment discontinuation between
ADHD pharmacotherapies and
placebo, however the proportion
of participants who withdrew due
to adverse events was
significantly higher among
participants who received any
ADHD pharmacotherapy.

effects of individual
pharmacotherapies

MPH

Nonmedicated adults with ADHD
showed considerable impairments
in memory function related to
executive control; adults treated
with MPH showed improved
memory function compared to the
nonmedicated group; healthy
adults without ADHD showed the
best memory function.

Pharmacotherapeutics improve
memory functions in adults with
ADHD, however they are still
impaired when compared with healthy
controls. Nonpharmacologic therapy,
in addition to pharmacotherapy, is
likely necessary to improve memory
functions.

Stimulant therapy is first-line for
adults with ADHD. Drug
holidays are not necessary for
adults. Non-stimulant therapy is
second-line for adult ADHD and
may be introduced as 1)
monotherapy in patients not suited
to stimulant therapy; 2)
augmenting treatment in
combination with stimulants; or 3)
treatment for comorbid
conditions. Combined
pharmacotherapy and
psychosocial therapy (CBT) is
recommended.
OROS MPH produced a
significantly greater decrease in
ADHD symptoms than placebo
(P<.001). Significantly more
individuals achieved remission on

Practitioners should employ combined
pharmacotherapy and psychosocial
therapy for adults with ADHD.

I

N=357;
OROS
methylphen
idate

I

Adult ADHD
Investigator Symptom
Rating Scale (AISRS);

OROS MPH,
18 mg/day
increasing to
individualize
d dose of 36

Use of OROS methylphenidate may
help adults with ADHD achieve
remission.
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Citation

Study Purpose

Pop (N)/
Sample
Size (n)
/Setting(s)

placebo-controlled study of
treatment for adult attentiondeficit/hyperactivity disorder:
Individualized dosing of osmoticrelease oral system (OROS)
methylphenidate with a goal of
symptom remission. Journal of
Clinical Psychiatry, 78(1), 105114.
https://doi.org/10.4088/JCP.15m1
0348

the approved
dose range for
osmotic-release
oral system
(OROS)
methylphenidat
e hydrochloride
in adults with
ADHD

(MPH),
N=141;
Placebo,
N=138
US

Goto, T, Hirata, Y., Takita, Y.,
Trzepacz, P. T., Allen, A. J.,
Song, D., Gau, S. S., Ichikawa,
H., Takahashi, M. (2017).
Efficacy and safety of
atomoxetine hydrochloride in
Asian adults with ADHD: A 10week randomized double-blind
placebo-controlled Asian study.
Journal of Attention Disorders,
21(2), 100–109.

To examine the
efficacy and
safety of
atomoxetine in
adult ADHD
patients from
Japan, Korea,
and Taiwan.

N=195
intervention
; N=196
placebo;
Asia

Design/
Level of
Evidence

I

Variables/
Instruments

Intervention

Findings

Clinical Global
ImpressionsImprovement (CGI-I);
Central Nervous System
Vital Signs (CNSVS);
Continuous
Performance Test
(CPT);
Shifting Attention Test
(SAT);
Symbol Digit
Modalities Test;
Behavior Rating
Inventory of Executive
Function-Adult
(BRIEF-A);
Adults ADHD Impact
Module (AIM-A);
Endicott Work
Productivity Scale
(EWPS);
Dyadic Adjustment
Scale (DAS);
Pittsburgh Sleep Quality
Index (PSQI);
Epworth Sleepiness
Scale (ESS);
InterSePT Scale for
Suicidal Thinking
(ISST-Plus)
CAARS-Inv; quality of
life (QoL); executive
function (EF)

mg, 54 mg,
or 72 mg/day
until AISRS
<18 or limit
of
tolerability;
Matching
placebo

symptoms using OROS MPH than
the placebo (P=.0008). OROS
methylphenidate did not appear to
negatively impact sleep compared
to placebo, however self-reported
feelings of insomnia.

Atomoxetine

With atomoxetine there was a
reduction in CAARS-Inv and
improvements in QoL and EF

Implications

Atomoxetine is an effective and
tolerable treatment for adults with
ADHD with low risk for adverse
effects.
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https://doi.org/10.1177/10870547
13510352
Groß, V., Lücke, C., Graf, E.,
Lam, A. P., Matthies, S., Borel,
P., Sobanski, E., Rösler, M., Retz,
W., Jacob, C., Colla, M., Huss,
M., Jans, T., Kis, B., Hamid, M.
A-, van Elst, L. T., & Philipsen,
A. (2019). Effectiveness of
psychotherapy in adult ADHD:
What do patients think? Results
of the COMPAS study. Journal of
Attention Disorders, 23(9), 1047–
1058.
https://doi.org/10.1177/10870547
17720718

Gutman, S. A., Balasubramanian,
S., Herzog, M., Kim, E.,
Swirnow, H., Retig, Y., & Wolff,
S. (2020). Effectiveness of a
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Study Purpose

Pop (N)/
Sample
Size (n)
/Setting(s)

Design/
Level of
Evidence

Variables/
Instruments

Intervention

Findings

Implications

Efficacy of
psychological
and
pharmacologica
l ADHD
treatments as
evaluated by
observer-rated
and patientrated symptom
change

7 study
sites in
Germany;
N=433

II

Patient-rated ADHD
symptoms, CAARSS:L; Clinical Global
Assessment-Efficacy
(CGA-E);
Observer-rated
CAARS-O:L; CGI-I;
CGA-E

ADHD-specific group
psychotherapy outperformed nonADHD specific individual
counseling post-treatment
(P=<.0001) and at follow-up
(P=.004).

Group ADHD therapy may be an
effective approach to symptom
improvement

To determine
whether a 7week tailored
occupationbased

N=11
intervention
;
N=12
control;

I

Adult attention deficit
hyperactivity disorder
self-report scale;
Perceived stress scale;

Group
therapy
(dialectical
behavior
therapy
(DBT) and
cognitive
behavior
therapy
(CBT), 22
sessions;
clinical
management
CM)
individual
counseling
without
structured
behavior
intervention
or
homework,
22 sessions;
pharmacolog
ic treatment
(double
blinded) with
methylpheni
date (MPH)
sustained
release
starting at 10
mg/day and
increased to
maximum
dosage of 1.3
mg/kg or
placebo
7 week
individual 1hour sessions

The intervention group revealed
statistical improvement in
perceived stress, ADHD
symptoms, COPM, and
satisfaction (P=.000)

An intervention focusing on routine
establishment, organization, time
management, stress management, and
sensory regulation in home and
community may be helpful for women
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Citation

Study Purpose

Pop (N)/
Sample
Size (n)
/Setting(s)

tailored intervention for women
with attention deficit
hyperactivity disorder (ADHD)
and ADHD symptoms: A
randomized controlled study.
American Journal of
Occupational Therapy, 74(1), 111.
https://doi.org/10.5014/ajot.2020.
033316

intervention can
reduce
perceived stress
and ADHD
symptoms and
enhance
perceived
performance of
and satisfaction
with daily roles
and activities
among women
with ADHD
To investigate
the efficacy of
mindfulnessbased cognitive
therapy
(MBCT) plus
treatment as
usual (TAU)
versus
treatment as
usual (TAU)
alone in
reducing core
symptoms in
adults with
ADHD

US

N=120;
MBCT,
N=60;
TAU,
N=60;
Netherlands

I

Mindfulnessbased
cognitive
therapy

MBCT + TAU revealed a
significant reduction in clinicianrated ADHD symptoms and the
effect was maintained until 6month follow-up. No
improvements were shown in the
domain of executive function
post-treatment, however there
were improvements at the 6
month follow-up.

Mindfulness-based cognitive therapy
may be an effective treatment option
in addition to treatment as usual for
adults with ADHD looking for
enhanced symptom improvement.

To examine
effects of
cognitivebehavior
therapy (CBT)
versus controls
in adults with
ADHD.

32 studies;
Country not
specified

I

Cognitivebehavior
therapy
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mine,
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a low effect size (SMD=0.24);
lisdexamfetamine small-tomedium effect size (SMD=0.34)
increasing to moderate effect
when removing cross-over studies
(SMD=0.50)
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Majority of individuals found
symptom improvement with CBT
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CBT is a viable option for symptom
reduction in adults with ADHD.
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the efficacy of bupropion as a
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